The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs

New antiviral drugs are needed for the treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients. These studies evaluated the in vitro and in vivo activity of the non-nucleosidic CMV inhibitor, BAY 38-4766, against guinea pig cytomegalovirus (GPCMV). Plaque reduction...

詳細記述

保存先:
書誌詳細
主要な著者: Schleiss, Mark R., Bernstein, David I., McVoy, Michael A., Stroup, Greg, Bravo, Fernando, Creasy, Blaine, McGregor, Alistair, Henninger, Kristin, Hallenberger, Sabine
フォーマット: Artigo
言語:Inglês
出版事項: 2005
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2768478/
https://ncbi.nlm.nih.gov/pubmed/15652969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2004.09.004
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料